Sartorius AG (ETR:SRT) has earned a consensus rating of “Hold” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is €114.88 ($133.58).
SRT has been the topic of a number of recent research reports. Berenberg Bank set a €110.00 ($127.91) target price on Sartorius and gave the stock a “neutral” rating in a research note on Friday, May 25th. Warburg Research set a €141.00 ($163.95) target price on Sartorius and gave the stock a “neutral” rating in a research note on Monday, May 28th. HSBC set a €94.00 ($109.30) price target on Sartorius and gave the company a “sell” rating in a report on Wednesday, May 30th. Commerzbank set a €100.00 ($116.28) price target on Sartorius and gave the company a “sell” rating in a report on Friday, June 15th. Finally, Deutsche Bank set a €125.00 ($145.35) price target on Sartorius and gave the company a “neutral” rating in a report on Friday, July 13th.
Shares of ETR:SRT traded up €4.50 ($5.23) during mid-day trading on Wednesday, hitting €138.00 ($160.47). The stock had a trading volume of 6,963 shares.
Sartorius Company Profile
Sartorius Aktiengesellschaft provides pharmaceutical and laboratory equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.
Further Reading: What is a Tariff?
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.